a six- to eight-week double-blind placebo-controlled trial of the potent and selective serotonin reuptake inhibitor fluvoxamine was conducted in 42 patients with primary obsessive-compulsive disorder ( ocd ) .
C0085228
fluvoxamine
C0028768
obsessive-compulsive disorder